179 related articles for article (PubMed ID: 18373730)
21. Combination Therapy for Chronic Hepatitis B: Current Updates and Perspectives.
Su TH; Liu CJ
Gut Liver; 2017 Sep; 11(5):590-603. PubMed ID: 28494575
[TBL] [Abstract][Full Text] [Related]
22. Pegylated Interferon Alfa-2b Add-on Treatment in Hepatitis B Virus Envelope Antigen-Positive Chronic Hepatitis B Patients Treated with Nucleos(t)ide Analogue: A Randomized, Controlled Trial (PEGON).
Chi H; Hansen BE; Guo S; Zhang NP; Qi X; Chen L; Guo Q; Arends P; Wang JY; Verhey E; de Knegt RJ; Xie Q; Janssen HLA
J Infect Dis; 2017 Apr; 215(7):1085-1093. PubMed ID: 28329061
[TBL] [Abstract][Full Text] [Related]
23. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine.
Papatheodoridis GV; Dimou E; Dimakopoulos K; Manolakopoulos S; Rapti I; Kitis G; Tzourmakliotis D; Manesis E; Hadziyannis SJ
Hepatology; 2005 Jul; 42(1):121-9. PubMed ID: 15962291
[TBL] [Abstract][Full Text] [Related]
24. Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues.
Buster EH; Schalm SW; Janssen HL
Best Pract Res Clin Gastroenterol; 2008; 22(6):1093-108. PubMed ID: 19187869
[TBL] [Abstract][Full Text] [Related]
25. Why do I treat HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues?
Papatheodoridis GV
Liver Int; 2013 Feb; 33 Suppl 1():151-6. PubMed ID: 23286859
[TBL] [Abstract][Full Text] [Related]
26. Long-term efficacy and safety of switching from lamivudine+adefovir to tenofovir disoproxil fumarate in virologically suppressed patients.
Fasano M; Maggi P; Leone A; Volpe A; Fiore JR; Angarano G; Santantonio TA
Dig Liver Dis; 2017 May; 49(5):530-534. PubMed ID: 28179096
[TBL] [Abstract][Full Text] [Related]
27. Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency.
Wong DK; Seto WK; Fung J; Ip P; Huang FY; Lai CL; Yuen MF
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1004-10.e1. PubMed ID: 23376799
[TBL] [Abstract][Full Text] [Related]
28. Peginterferon Is Superior to Nucleos(t)ide Analogues for Prevention of Hepatocellular Carcinoma in Chronic Hepatitis B.
Liang KH; Hsu CW; Chang ML; Chen YC; Lai MW; Yeh CT
J Infect Dis; 2016 Mar; 213(6):966-74. PubMed ID: 26582959
[TBL] [Abstract][Full Text] [Related]
29. Treatment of HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues.
Papatheodoridis GV
Liver Int; 2011 Jan; 31 Suppl 1():95-103. PubMed ID: 21205145
[TBL] [Abstract][Full Text] [Related]
30. Three-year efficacy and safety of tenofovir in nucleos(t)ide analog-naïve and nucleos(t)ide analog-experienced chronic hepatitis B patients.
Wang HM; Hung CH; Lee CM; Lu SN; Wang JH; Yen YH; Kee KM; Chang KC; Tseng PL; Hu TH; Chen CH
J Gastroenterol Hepatol; 2016 Jul; 31(7):1307-14. PubMed ID: 26758501
[TBL] [Abstract][Full Text] [Related]
31. Potent hepatitis B surface antigen response to treatment of hepatitis-B-e-antigen-positive chronic hepatitis B with α-interferon plus a nucleos(t)ide analog.
Chen X; Cao Z; Liu Y; Zhang H; Zhang Y; Ma L; Jin Y; Yu H; Ma B; Zheng Y; Wu H
J Gastroenterol Hepatol; 2012 Mar; 27(3):481-6. PubMed ID: 22098411
[TBL] [Abstract][Full Text] [Related]
32. Current therapy with nucleoside/nucleotide analogs for patients with chronic hepatitis B.
Xu XW; Chen YG
Hepatobiliary Pancreat Dis Int; 2006 Aug; 5(3):350-9. PubMed ID: 16911930
[TBL] [Abstract][Full Text] [Related]
33. Impact of nucleos(t)ide analogues on the estimated glomerular filtration rate in patients with chronic hepatitis B: a prospective cohort study in China.
Qi X; Wang JY; Mao RC; Zhang JM
J Viral Hepat; 2015 Jan; 22(1):46-54. PubMed ID: 25402626
[TBL] [Abstract][Full Text] [Related]
34. Partial virological response to entecavir treatment in nucleos(t)ide-naïve patients with HBeAg-positive chronic hepatitis B is not caused by reduced sensitivity.
Li X; Li F; Zhang Y; Kang Y; Yu J; Yang F; Liu H; Qin Y; Huang Y; Mao R; Zhang J
Biochem Biophys Res Commun; 2015 Sep; 464(4):1185-1191. PubMed ID: 26212437
[TBL] [Abstract][Full Text] [Related]
35. Clinical course of chronic hepatitis B patients receiving nucleos(t)ide analogues after virological breakthrough during monotherapy with lamivudine.
De Francesco MA; Gargiulo F; Spinetti A; Zaltron S; Giagulli C; Caccuri F; Castelli F; Caruso A
New Microbiol; 2015 Jan; 38(1):29-37. PubMed ID: 25742145
[TBL] [Abstract][Full Text] [Related]
36. Long-term efficacy of tenofovir disoproxil fumarate therapy after multiple nucleos(t)ide analogue failure in chronic hepatitis B patients.
Kim HJ; Cho JY; Kim YJ; Gwak GY; Paik YH; Choi MS; Koh KC; Paik SW; Yoo BC; Lee JH
Korean J Intern Med; 2015 Jan; 30(1):32-41. PubMed ID: 25589833
[TBL] [Abstract][Full Text] [Related]
37. Monitoring of genotypic resistance profile in chronic hepatitis B patients receiving nucleos(t)ide analogues in Huzhou, China.
Qian F; Qin J; Li D; Ma Z; Zhang H; Jin F; Wang W
J Infect Dev Ctries; 2016 Sep; 10(9):996-1002. PubMed ID: 27694733
[TBL] [Abstract][Full Text] [Related]
38. Prevalence and risk factors for viral blipping in chronic hepatitis B patients treated with nucleos (t) ide analogues.
Brahmania M; Brouwer WP; Hansen T; Mazzulli T; Feld J; Wong D; Kowgier M; Janssen HL
J Viral Hepat; 2016 Dec; 23(12):1003-1008. PubMed ID: 27502526
[TBL] [Abstract][Full Text] [Related]
39. [Drug resistance, genotype, and serotype of hepatitis B virus in nucleos(t)ide analogue naive patients with chronic hepatitis B].
Li XG; Xu J; Liu BM; Yang JX; Yan L; Li T; Zhuang H
Zhonghua Gan Zang Bing Za Zhi; 2010 Feb; 18(2):92-5. PubMed ID: 20196945
[TBL] [Abstract][Full Text] [Related]
40. Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients.
He LT; Ye XG; Zhou XY
World J Gastroenterol; 2016 Dec; 22(46):10210-10218. PubMed ID: 28028369
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]